{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-041689","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-09-08T11:05:42+00:00","discovered_at":"2026-09-08T11:10:00.253664+00:00","generated_at":"2026-09-08T11:10:08.681382+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Tonix Pharmaceuticals promotes Thomas Englese to Chief Commercial Officer","bullets":["Thomas Englese appointed Chief Commercial Officer, effective Sept 8, 2026, after serving as EVP Commercial Operations since 2024.","Englese oversees commercial organization for TONMYA (fibromyalgia) and migraine products Zembrace SymTouch and Tosymra.","Previous roles include CCO at Tris Pharma and Aziyo, and SVP/GM at Mallinckrodt.","CEO Seth Lederman cites Englese's role in TONMYA launch; focus on expanding access and sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-041689","json":"https://secwatch.observer/filing/0001493152-26-041689.json","markdown":"https://secwatch.observer/filing/0001493152-26-041689.md","text":"https://secwatch.observer/filing/0001493152-26-041689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226041689/0001493152-26-041689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226041689/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T11:10:08.681382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}